However, in the subgroup with liver biopsy as a diagnostic method, patients with NAFLD had no statistically significant difference in circulating RBP4 levels compared to non-NAFLD (SMD -0.38; 95% CI: − 1.02–0.25; P = 0.235). This evidence concerns the gene RBP4 and metabolic dysfunction-associated steatotic liver disease.